Skip to main content
OpenTrials
Completed

NCT Number: NCT03160482

PACE4 in Thyroid Cancer

The investigation of thyroid nodules is limited by the fact that up to 49% of the fine needle aspirations (FNA) performed are of "indeterminate cytological signification". Moreover, no fully reliable molecular marker for thyroid cancer have been described. The goal of this project is to study the expression of a specific kind of protein convertase in benign and in malignant thyroid nodules to determine its potential as a biomarker.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Thyroid Nodule Endocrine Gland Neoplasms Endocrine System Diseases Head and Neck Neoplasms Neoplasms Neoplasms by Site Thyroid Diseases Thyroid Neoplasms

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CIUSSS de l'Estrie - CHUS

Sherbrooke, Quebec, J1G 2E8, Canada

About this study

Patients that underwent thyroidectomy at the CIUSSS de l'Estrie-CHUS will be recruited and classified according to the pathological diagnosis. An immunohistochemistry technique, developed and calibrated for the specific protein convertase studied, will be undertaken. Results will be interpreted by a specialized pathologist.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men of women, aged 18-100 y.-o.
  • History of subtotal or total thyroidectomy at the "Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke" (CIUSSS de l'Estrie - CHUS) between January 2010 and May 2016.

Exclusion criteria

  • Refusal to participate to the study.
  • Unavailability of the formalin-fixed, paraffin-embedded tissues.
  • Uncertain pathological diagnosis.

Treatment and study plan

Immunohistochemistry

Diagnostic Test

Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Primary outcomes

  1. Expression pattern of the studied protein convertase

    Time frame: Trough study completion, an average of 1 year after the patients have been operated.

    Horseradish peroxidase staining with specific antibodies.

Sponsors and collaborators

Lead sponsor

Robert Day

Other

Registry information

Official study title

Evaluation of PACE4 Isoforms as Biomarkers in Thyroid Cancer

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
May 19, 2017
Registry last updated
Oct 2, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.